With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5317-33-9,3-(4-Methylpiperazin-1-yl)propan-1-ol,as a common compound, the synthetic route is as follows.,5317-33-9
A solution of MsCl ( 0.80 g, 7.00 mmol) in DCM (10 mL) was added dropwise to a stirred, ice- cold suspension of 3-(4-methylpiperazin-l-yl)propan-l-ol (1.00 g, 6.32 mmol) in DCM (5 mL). The reaction was stirred at room temperature for 2 h before the solvent was removed under vacuum. The crude product (white solid) was used directly without purification (1.4 g, 94% yield). ‘H NMR (500 MHz, CD3OD SPE) S: 4.38 (t, J= 5.9 Hz, 2H), 3.73 (dd, J= 22.6, 16.8 Hz, 8H), 3.44 – 3.38 (m, 2H), 3.13 (s, 3H), 3.02 (s, 3H), 2.31 – 2.23 (m, 2H).
As the paragraph descriping shows that 5317-33-9 is playing an increasingly important role.
Reference：
Patent; ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD; SUN, Sanxing; ZHAO, Long; HU, Chongbo; CHEN, Zhengshu; YE, Jinqi; (0 pag.)WO2020/2969; (2020); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics